News
Public · Published
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Nxera Pharma's UK subsidiary signed an exclusive global license agreement giving AbbVie rights to develop and sell NXE0033744 for inflammatory bowel disease. Nxera will receive US$100 million upfront, may receive up to US$1.37 billion in development and sales milestones, and is eligible for tiered royalties. The deal requires customary antitrust clearances.
Published:
Updated:
What happened
Nxera Pharma’s UK subsidiary signed an exclusive global license agreement giving AbbVie rights to develop and sell NXE0033744 for inflammatory bowel disease. Nxera will receive US$100 million upfront, may receive up to US$1.37 billion in development and sales milestones, and is eligible for tiered royalties. The deal requires customary antitrust clearances.
Confirmed
Global impact / market context
The US$100 million upfront payment is expected to add materially to Nxera’s revenue in the fourth quarter of 2026, subject to auditor agreement. Later milestones and royalties depend on development progress and sales, so they offer potential additional income but are not assured.
Analyst inference
The agreement transfers worldwide development and commercialization rights to AbbVie while giving Nxera upfront and possible future payments. For investors, the immediate revenue contribution is clearer than the longer-term value, which depends on regulatory clearance, successful development, and eventual sales of the investigational drug.
Analyst inference
What to watch
- Whether customary antitrust clearances, including under the Hart-Scott-Rodino Act, are obtained, since the agreement is subject to these approvals before it can proceed. Confirmed
- Whether Nxera recognizes the US$100 million upfront payment as revenue in the fourth quarter of 2026, as expected, subject to agreement with its auditors. Confirmed
- Development progress and any resulting milestones will determine whether Nxera receives payments beyond the upfront amount; eventual royalties also depend on commercial sales. Analyst inference